Lantheus (NASDAQ:LNTH) Upgraded by William Blair to “Outperform” Rating

Lantheus (NASDAQ:LNTH) was upgraded by equities researchers at William Blair from a “market perform” rating to an “outperform” rating in a note issued to investors on Thursday, MarketBeat Ratings reports.

Other equities research analysts have also recently issued reports about the company. Citizens Jmp increased their price objective on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday. Mizuho raised their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a research note on Tuesday. Truist Financial increased their price objective on shares of Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $78.83.

Lantheus Stock Down 0.3%

Shares of NASDAQ:LNTH traded down $0.25 during trading on Thursday, reaching $75.47. 1,150,332 shares of the stock traded hands, compared to its average volume of 841,698. The stock has a market cap of $5.00 billion, a P/E ratio of 31.82 and a beta of -0.08. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The stock has a 50-day moving average of $67.76 and a two-hundred day moving average of $59.90. Lantheus has a 52-week low of $47.25 and a 52-week high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The business had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. During the same period in the prior year, the firm posted $1.59 EPS. The firm’s quarterly revenue was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, sell-side analysts expect that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in LNTH. M&T Bank Corp purchased a new position in shares of Lantheus during the 4th quarter worth $370,950,000. Farallon Capital Management LLC raised its holdings in Lantheus by 56.1% in the 4th quarter. Farallon Capital Management LLC now owns 5,427,479 shares of the medical equipment provider’s stock worth $361,199,000 after purchasing an additional 1,950,252 shares during the period. Assenagon Asset Management S.A. purchased a new position in Lantheus during the third quarter valued at $65,654,000. Norges Bank bought a new stake in Lantheus during the fourth quarter valued at about $76,197,000. Finally, Polaris Capital Management LLC bought a new stake in Lantheus during the third quarter valued at about $32,687,000. 99.06% of the stock is currently owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.